Catastrophic Antiphospholipid Syndrome: Immediate Management
Initiate triple therapy immediately with glucocorticoids, intravenous heparin, and plasma exchange and/or intravenous immunoglobulin (IVIG) without waiting for confirmatory laboratory results if clinical suspicion is high. 1
Core Treatment Components
First-Line Triple Therapy
The foundation of CAPS management requires simultaneous administration of three therapeutic modalities 2:
- Anticoagulation with intravenous heparin (not oral anticoagulants initially) - this is the only intervention with demonstrated significant prognostic impact 3
- High-dose glucocorticoids (typically methylprednisolone 500-1000 mg IV daily for 3 days, followed by 1-2 mg/kg/day prednisone equivalent) 1, 2
- Plasma exchange - particularly critical given its association with improved patient survival in retrospective studies 1
Anticoagulation Strategy
- Use therapeutic-dose intravenous unfractionated heparin during the acute phase for easier reversal if needed 2
- Transition to warfarin (target INR 2.5) for long-term management, NOT direct oral anticoagulants (DOACs) 1, 4
- DOACs are inferior to warfarin in preventing thromboembolic events in antiphospholipid syndrome and should be avoided 1, 4
- Maintain overlapping parenteral anticoagulation when initiating warfarin 4
Additional Considerations
Associated Systemic Lupus Erythematosus
If CAPS occurs in the context of SLE, add cyclophosphamide to the treatment regimen 5, 3
Refractory or Relapsing Disease
For patients not responding to standard triple therapy, consider 1, 2, 5:
- Rituximab (anti-CD20 monoclonal antibody) - emerging evidence supports efficacy in catastrophic APS 1, 5, 3
- Eculizumab (complement C5 inhibitor) - complement activation is involved in tissue injury pathogenesis, and emerging evidence supports its use 1, 3
- These agents may be used alone or in combination for refractory cases 2
Critical Clinical Pitfalls
Diagnostic Delays
- Do not delay treatment waiting for antiphospholipid antibody results - CAPS patients are often too critically ill to wait for laboratory confirmation 2
- Diagnosis requires rapid-onset thrombosis affecting multiple organs simultaneously with high mortality (may exceed 50%) 2, 6
- Look for small vessel occlusions on histopathology and evidence of multiorgan dysfunction 2, 7
Triggering Factors
Identify and treat precipitating factors aggressively 2, 6:
- Infection (most common trigger - requires concurrent antimicrobial therapy)
- Recent surgery or trauma
- Anticoagulation discontinuation
- Active malignancy
Anticoagulation Errors
- Never use DOACs in confirmed antiphospholipid syndrome - the evidence shows inferiority to warfarin 1, 4
- Avoid estrogen-containing contraceptives due to increased clotting risk 1
Monitoring and Ongoing Care
- Maintain therapeutic anticoagulation with appropriate INR monitoring (target 2.5) to prevent recurrence 6
- Continue long-term anticoagulation with warfarin indefinitely given the high risk of recurrent thrombosis 1
- Monitor for organ dysfunction in kidneys, lungs, central nervous system, and heart - the most commonly affected organs 6
Prognosis
Despite aggressive treatment, CAPS carries mortality exceeding 50% in some series 2. However, early recognition and immediate initiation of triple therapy has significantly improved survival rates 6. The combination of anticoagulation, immunosuppression, and plasma exchange remains the cornerstone of management, with newer targeted therapies (rituximab, eculizumab) reserved for refractory cases 2, 5, 3.